Chicago, Illinois 60611

  • Small Intesti


RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

Study summary:

OBJECTIVES: - Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. - Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.


DISEASE CHARACTERISTICS: - Inoperable bowel obstruction secondary to cancer OR - Metastatic or primary abdominal cancer - Patient presents with vomiting - Percutaneous gastrostomy tube allowed PATIENT CHARACTERISTICS: Age: - Over 18 Performance status: - ECOG 0-4 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Other: - No documented hypersensitivity to octreotide - Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Prior chemotherapy allowed Endocrine therapy: - Concurrent steroids allowed Radiotherapy: - Prior radiotherapy allowed Surgery: - Not specified



Primary Contact:

Study Chair
J. Cameron Muir, MD
Robert H. Lurie Cancer Center

Backup Contact:


Location Contact:

Chicago, Illinois 60611
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.